Spectral Analysis of Human Retinal Pigment Epithelium Cells in Healthy and AMD Eyes.

Journal Information

Full Title: Invest Ophthalmol Vis Sci

Abbreviation: Invest Ophthalmol Vis Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Evidence found in paper:

"the source codes for all applied plugins are available via the fiji/imagej updater ( https://research stowers org/imagejplugins/updates/ ) or via the developer's website ( https://research stowers org/imagejplugins/zipped_plugins html )."

Evidence found in paper:

"Disclosure: L. Bourauel, None; M. Vaisband, None; L. von der Emde, None; K. Bermond, None; I.S. Tarau, None; R. Heintzmann, None; F.G. Holz, Acucela (C, F), Alexion (C), Allergan (F), Alzheon (C), Apellis (C, F), Astellas (C), Bayer (C, F), Boehringer Ingelheim (C), CenterVue (F), Formycon/Bioeq (C, F), Genentech (C, F), Geuder (C, F), GRADE Reading Center (O), Graybug (C), Gyroscope (C), Heidelberg Engineering (C, F), Iveric Bio (C, F), Janssen (C), Kanghong (C, F), Lin Bioscience (C), NightstaRx (F), Novartis (C, F), Optos (F), Oxurion (C), Pixium Vision (C, F), Stealth BioTherapeutics (C), Zeiss (C, F); C.A. Curcio, Apellis (C), Astellas (C), Boehringer Ingelheim (C), Heidelberg Engineering (F), Regeneron (F); J. Hasenauer, None; T. Ach, Apellis Pharmaceuticals (C), Bayer (C), Nidek (R), Novartis (C, R), Roche (C)"

Evidence found in paper:

"Supported by the Werner Jackstädt Foundation (TA); by a grant from the National Eye Institute, National Institutes of Health (1R01EY027948; TA, CAC); and by the A. Döllner Foundation (TA)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025